Has Ilya Leyngold, MD received payments from drug or device companies?

Yes. Drug and device makers reported $27,435 in general payments to Ilya Leyngold, MD across 98 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Ilya Leyngold, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Ilya Leyngold, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Ilya Leyngold, MD

Ophthalmic Plastic and Reconstructive Surgery · Meridian, IDNPI 1407996176

Payments from drug & device makers

$27,435in general payments, 2019–2025

Across 98 payments — averaging $279.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Amgen$11K
Axogen$10K
Osteomed LLC$5K
Mentor Worldwide LLC$241
Revance Therapeutics, Inc.$210
Johnson & Johnson$168
plus $621 from 8 others

What the payments were for

Consulting fees$10,98540%
Speaking & faculty fees$11,62542%
Travel & lodging$1,1534%
Food & beverage$3,57013%
Education$1020%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Amgen(2 entities)	46	$10,852
Axogen	15	$10,302
Osteomed LLC	3	$5,041
Mentor Worldwide LLC	6	$241
Revance Therapeutics, Inc.	5	$210
Johnson & Johnson(2 entities)	3	$168
Argenx US, Inc.	1	$125
Galderma Laboratories, L.p.	6	$115
AbbVie	3	$113
Biotissue Holdings Inc.	2	$91
Boston Scientific	3	$55
Dompe US, Inc.	2	$51
Stryker	2	$43
Baxter Healthcare	1	$28

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few ophthalmic plastic and reconstructive surgery providers in Idahoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024

$586,906

Medicare patients

125

Services billed

1,956

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
ErythromycinErythromycin Base	167	$1,748
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha	94	$1,308
Celecoxib	86	$1,195
Ondansetron OdtOndansetron	32	$322
Methylprednisolone	18	$126
Oxycodone Hcl	25	$92

Paid to pharmacies, not to this prescriber.

Other ophthalmic plastic and reconstructive surgery in Meridian

Caroline VargasonNampa$625
Samuel BecksteadIdaho Falls$534
Carolee Cutler PeckAmmon$273

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →